Literature DB >> 4293743

The epizootiology of the vesicular stomatitis viruses: a reappraisal.

A H Jonkers.   

Abstract

Entities:  

Mesh：

Year:  1967        PMID： 4293743     DOI： 10.1093/oxfordjournals.aje.a120738

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN： 0002-9262            Impact factor:   4.897


× No keyword cloud information.
  8 in total

Review 1.  Live virus vaccines based on a vesicular stomatitis virus (VSV) backbone: Standardized template with key considerations for a risk/benefit assessment.

Authors:  David K Clarke; R Michael Hendry; Vidisha Singh; John K Rose; Stephen J Seligman; Bettina Klug; Sonali Kochhar; Lisa Marie Mac; Baevin Carbery; Robert T Chen
Journal:  Vaccine       Date:  2016-07-06       Impact factor: 3.641

Review 2.  Vesicular diseases: recent advances and concepts of control.

Authors:  W A Watson
Journal:  Can Vet J       Date:  1981-10       Impact factor: 1.008

3.  Trajectory analysis of winds and vesicular stomatitis in North America, 1982-5.

Authors:  R F Sellers; A R Maarouf
Journal:  Epidemiol Infect       Date:  1990-04       Impact factor: 2.451

4.  Prime-boost vaccination with recombinant mumps virus and recombinant vesicular stomatitis virus vectors elicits an enhanced human immunodeficiency virus type 1 Gag-specific cellular immune response in rhesus macaques.

Authors:  R Xu; F Nasar; S Megati; A Luckay; M Lee; S A Udem; J H Eldridge; M A Egan; E Emini; D K Clarke
Journal:  J Virol       Date:  2009-07-22       Impact factor: 5.103

5.  Neurovirulence and immunogenicity of attenuated recombinant vesicular stomatitis viruses in nonhuman primates.

Authors:  David K Clarke; Farooq Nasar; Siew Chong; J Erik Johnson; John W Coleman; Margaret Lee; Susan E Witko; Cheryl S Kotash; Rashed Abdullah; Shakuntala Megati; Amara Luckay; Becky Nowak; Andrew Lackner; Roger E Price; Peter Little; Narender Kalyan; Valerie Randolf; Ali Javadian; Timothy J Zamb; Christopher L Parks; Michael A Egan; John Eldridge; Michael Hendry; Stephen A Udem
Journal:  J Virol       Date:  2014-04-02       Impact factor: 5.103

6.  Vaccination With a Highly Attenuated Recombinant Vesicular Stomatitis Virus Vector Protects Against Challenge With a Lethal Dose of Ebola Virus.

Authors:  Demetrius Matassov; Andrea Marzi; Terri Latham; Rong Xu; Ayuko Ota-Setlik; Friederike Feldmann; Joan B Geisbert; Chad E Mire; Stefan Hamm; Becky Nowak; Michael A Egan; Thomas W Geisbert; John H Eldridge; Heinz Feldmann; David K Clarke
Journal:  J Infect Dis       Date:  2015-06-24       Impact factor: 5.226

Review 7.  Recombinant vesicular stomatitis virus as an HIV-1 vaccine vector.

Authors:  David K Clarke; David Cooper; Michael A Egan; R Michael Hendry; Christopher L Parks; Stephen A Udem
Journal:  Springer Semin Immunopathol       Date:  2006-09-15

8.  rVSVΔG-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein: Standardized template with key considerations for a risk/benefit assessment.

Authors:  Thomas P Monath; Patricia E Fast; Kayvon Modjarrad; David K Clarke; Brian K Martin; Joan Fusco; Richard Nichols; D Gray Heppner; Jakub K Simon; Sheri Dubey; Sean P Troth; Jayanthi Wolf; Vidisha Singh; Beth-Ann Coller; James S Robertson
Journal:  Vaccine X       Date:  2019-01-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.